Bioactive Products
| A unique collection of 518 natural compounds with Antioxidants biological activity for high throughput screening (HTS) and high content screening (HCS) | ||
| Catalog No: | B11 | Antioxidants Compound Library Screening Details |
| Size: | 1mg/well * 518 Compounds 2mg/well * 518 Compounds | |
| Cat. No. | Information |
| CFN97735 | Olivetol Olivetol is a precursor in various syntheses of tetrahydrocannabinol. It acts as a competitive inhibitor of the cannabinoid receptors CB1 and CB2. Olivetol has antioxidant effects. |
| CFN97748 | Cycloheterophyllin Cycloheterophyllin has an antioxidant effect, it is a photoprotective agent that inhibits ultraviolet A (UVA)-induced oxidative stress and damage, and could be used in the research on and prevention of skin photoaging. Cycloheterophyllin exerts a concentration-dependent inhibition of neutrophil cytosolic protein kinase C (PKC) and rat brain PKC by the O2- generation in rat neutrophils, but has no effect on porcine heart protein kinase A (PKA).It also shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation, due to an inhibitory effect on cyclooxygenase. |
| CFN97749 | Hexahydrocurcumin Hexahydrocurcumin has in vitro antioxidant and anti-inflammatory activities, it has potential beneficial effects as a food and/or dietary supplement. Hexahydrocurcumin has cytotoxic effect, may prove useful in cancer prevention, it together with 5-fluorouracil exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer. Hexahydrocurcumin is also an anti-atherosclerogenic agent in humans, can inhibit platelet aggregation in the treatment of human platelet-rich plasma. |
| CFN90315 | Breviscapine Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway . |
| CFN90317 | Capillarisin Capillarisin is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells, it inhibits cancer cell growth of osteosarcoma cells by inducing apoptosis accompanied with G0/G1-phase cell cycle arrest and loss in mitochondrial membrane potential.Capillarisin has anti-inflammatory activity, can inhibit LPS-induced inflammation by blocking TLR4-mediated NF-κB and MAPKs activation in BV2 microglia. Capillarisin possesses promising anti-hyperalgesic and anti-allodynic effects through the inhibition of various inflammatory pain signaling. |
